Molecular genetic aspects of the phakomatoses: tuberous sclerosis complex and neurofibromatosis 1

2001 ◽  
Vol 14 (2) ◽  
pp. 163-169 ◽  
Author(s):  
Mia MacCollin ◽  
David Kwiatkowski
2021 ◽  
pp. 98-105
Author(s):  
Julie Loft Nagel ◽  
Maja Patricia Smerdel ◽  
Lisbeth Birk Møller ◽  
Lotte Andreasen ◽  
Anette Bygum

Tuberous sclerosis complex (TSC) is an autosomal dominant hereditary disease with hamartomatous growths in multiple organs due to loss-of-function variants in TSC1 or TSC2. In approximately 15% of patients with clinical TSC, no pathogenic variant can be identified, and low-level mosaicism is suggested to be one of the reasons. Mosaicism is well-known in TSC and challenges the molecular genetic diagnosis. The advent of next-generation sequencing has improved the diagnostics in TSC including in patients with mosaicism. The TSC phenotype varies widely, and mosaic patients with TSC are often considered to have a milder phenotype. Here, the authors describe a patient with mosaic TSC with a 10% variant allele fraction and manifestations in three organ systems (skin, eyes, and kidneys). Furthermore, the authors studied existing literature about phenotypic organ manifestations in patients with mosaic TSC. No clear definition of the phenotype of patients with mosaic TSC could be established, but unilateral angiofibromas and the absence of tubers and a subependymal nodule could indicate mosaicism. The case shows that patients with low-level mosaic TSC can have multiple affected organ systems though still a mild clinical picture.


2004 ◽  
Vol 19 (9) ◽  
pp. 699-709 ◽  
Author(s):  
Kit-Sing Au ◽  
Aimee T. Williams ◽  
Michael J. Gambello ◽  
Hope Northrup

2021 ◽  
Vol 48 (2) ◽  
pp. 29-36
Author(s):  
B. Georgieva ◽  
M. Koleva ◽  
T. Todorov ◽  
V. Bojinova ◽  
D. Deneva ◽  
...  

Abstract Objective The aim of the study was to determine the molecular-genetic characteristics of the autosomal dominant systematic disorder Tuberous Sclerosis Complex (TSC1 and TSC2) in Bulgarian patients and to derive some genotype-phenotype correlations. Material and Methods In total 42 patients/families with suspected clinical diagnosis of TSC were analyzed. We used direct sequencing and MLPA for the TSC1 and TSC2 gene analysis. Results In 38 families (90.5%) we confirmed the suspected clinical diagnosis – 15 with TSC1 (35.7%) and 23 (54.8%) with TSC2. In 4 families (9.5%) pathogenic variants were not found. In all 38 patients with proven diagnosis of TSC, we found 38 different mutations, 15 of which (39%) were detected for the first time by our research group. The mutation “hotspots“ in TSC1 gene are exons 9, 15, 17 and 18, where 73% of the TSC1 mutations are localized, while the TSC2 gene mutation “hotspots“ are exons 13 and 34, with 22% of the mutations situated there. In the TSC2 patients the common clinical findings include subcortical tubers, epilepsy with generalized tonic-clonic seizures, subependymal giant cell astrocytoma, facial angiofibromas, ungual fibromas, cardiac rhabdomyomas and renal angiomyolipomas, while in the TSC1 patients typically cortical tubers, cortical dysplasia and subependymal nodules were registered. In patients with aggressive frameshift and nonsense TSC1 and TSC2 mutations commonly hypomelanotic macules, cortical and subcortical tubers, cortical dysplasia, epilepsy with different types of seizures were found. Renal angiomyolipomas and cysts were detected mainly in patients with large deletions. Shagreen patches and intellectual disability were typically registered in equal degree in patients with frameshift, nonsense and missense mutations. Conclusion Although some genotype-phenotype correlations were derived, there is a great inter- and intrafamilial clinical variability in TSC, so it is impossible to predict the course of the disease on the basis of the detected molecular defect. The obtained results helped us to develop a diagnostic algorithm for proper molecular-genetic diagnostics which permits adequate genetic counseling, prophylaxis and treatment in the affected TSC families.


2017 ◽  
Vol 06 (03) ◽  
pp. 164-168
Author(s):  
Tarek Jallol ◽  
Mohammed Chaudhary ◽  
Husam Muhaish ◽  
Miral Mashhour ◽  
Raidah Baradie ◽  
...  

AbstractTuberous sclerosis complex (TSC) is a neurocutaneous syndrome with an autosomal dominant pattern of inheritance. It is a multisystem genetic disease caused by mutations in the TSC1 and TSC2 genes. The neuroradiographic findings of TSC include cortical dysplasia (cortical tubers and cerebral white matter radial migration lines), subependymal nodules, and subependymal giant cell astrocytoma. In this article, we describe an interesting case of TSC with an extremely rare radiographic finding of focal right megalencephaly. Molecular genetic testing detected a heterozygous c.3814+2T>G (p.?) variant, not previously described in the literature. As per the 2012 International Tuberous Sclerosis Complex Consensus Group guidelines and the findings of the genetic testing, this mutation most probably should be considered as a pathogenic variant. There are few cases of hemimegalencephaly (HME) reported in the literature, associated with TSC. To our knowledge focal megalencephaly is an extremely rare neuroradiographic finding in patients with TSC and has been previously reported only once by Griffiths et al based on clinical diagnostic criteria. Despite the uncommon association, TSC is the only neurocutaneous syndrome with similar histological appearance to HME. It is recognized that the pathological features in TSC and HME are due to abnormal cell proliferation, migration, and organization which could also be a possible mechanism for the development of focal megalencephaly. The uncommon association of HME and TSC with cytological similarities makes us wonder if there could be similarities in the pathogenesis of these two conditions. The advances in molecular genetic testing, increasing use of next-generation sequencing, and discovery of new pathogenic variants could answer some of these questions.


Sign in / Sign up

Export Citation Format

Share Document